吉西他滨
胰腺癌
癌症研究
谷氨酰胺
转移
癌症
医学
糖酵解
胰腺导管腺癌
药物代谢
腺癌
生物
新陈代谢
肿瘤科
生物信息学
药理学
内科学
生物化学
氨基酸
作者
Jingcheng Zhang,Yutong Wang,Lejunzi Wang,Lei You,Taiping Zhang
标识
DOI:10.1097/cm9.0000000000002758
摘要
As pancreatic cancer (PC) is highly malignant, its patients tend to develop metastasis at an early stage and show a poor response to conventional chemotherapies. First-line chemotherapies for PC, according to current guidelines, include fluoropyrimidine- and gemcitabine-based regimens. Accumulating research on drug resistance has shown that biochemical metabolic aberrations in PC, especially those involving glycolysis and glutamine metabolism, are highly associated with chemoresistance. Additionally, lipid metabolism is a major factor in chemoresistance. However, emerging compounds that target these key metabolic pathways have the potential to overcome chemoresistance. This review summarizes how PC develops chemoresistance through aberrations in biochemical metabolism and discusses novel critical targets and pathways within cancer metabolism for new drug research.
科研通智能强力驱动
Strongly Powered by AbleSci AI